Opko Health Inc (NASDAQ:OPK) does about 11.67M shares in volume on a normal day but saw 8678670 shares change hands in Monday trading. The company now has a market cap of 975.79M USD. Its current market price is $1.40, marking an increase of 3.70% compared to the previous close of $1.35. The 52 week high reached by this stock is $2.24 whilst the lowest price level in 52 weeks is $0.85.
Opko Health Inc (OPK) has a 20-day trading average at $1.0750 and the current price is -37.50% off the 52-week high compared with 64.40% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0285 and its 200-day simple moving average is $1.4366. If we look at the stock’s price movements over the week, volatility stands at 5.95%, which increases to 6.59% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 81.67 to suggest the stock is overbought.
The consensus objective for the share price is $4.25, suggesting that the stock has a potential upside of 67.06% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 29, 2023 when Barrington Research upgraded the stock to “Outperform” and issued a price target of $2.
Opko Health Inc (OPK) stock is up 6.87% over the week and 47.17% over the past month. Its price is -7.28% year-to-date and -4.11% over the past year.
OPK’s earnings per share are forecast to shrink by -48.00% this year and 29.70% over next year. Expected sales for next quarter are $187.04 million, which analysts say will come at $760.31 million for the current fiscal year and next year at $838.08 million. In addition, estimates put the company’s current quarterly revenue at an average of $182.99 million.
To reach the target analysts have set, the stock logically needs to grow 67.06 percent from here.
Outstanding shares total 773.28M with insiders holding 52.41% of the shares and institutional holders owning 25.17% of the company’s common stock. The company has a return on investment of -11.29% and return on equity of -12.80%. The beta has a value of 1.82. Price to book ratio is 0.78 and price to sales ratio is 1.13.
